Genomill is redefining genetics,
by providing state-of-the-art solutions
for significant medical challenges

ABOUT US

Genetics is our first language

Genomill Health is a full scale genetic service and R&D company providing state-of- the-art solutions for significant medical challenges, such as liquid biopsies for oncologists. Our genetic service concept is a unique solution for accessible clinical use of genetics for healthcare sector actors.

Our digital one-stop-solution enables clinics to use validated genetic tests in different therapeutic areas under same platform and it covers the whole process from ordering & logistics to delivering the results in a secure environment. It makes the use of genetics easy for any clinic as it includes a wide portfolio of tests and genetic counseling. Currently our test portfolio covers the following therapeutic areas:

Oncology – Cardiology – Ophthalmology – Gastroenterology – Internal Medicine – Pharmacogenetics – Reproductive Health

Genomill Health R&D is focused on streamlining and developing NGS based genetic testing. By these we are redefining clinical genetics.

Our Team consists of experts in medicine, bioscience, genetics and diagnostics, as well as business and law.

We share our Vision with our collaborators – to democratize the use of genetic information and to make high-quality clinical genomics widely available. We believe everyone is entitled to high quality accessible genetics, ultimately leading to improved clinical outcomes and quality of life. Promoting this goal is the ultimate driver for us.

TEAM

Kalle Koskinen

Kalle Koskinen

CEO

Mr. Koskinen is the CEO of Genomill Health and is responsible for general management, business development and finance and administration. He has several years international experience in commercial functions within Pharmaceutical companies and Medical device industries in global, regional and local roles, in Sweden, Denmark, Switzerland and Brazil. Mr. Koskinen holds double Master´s degrees, in Business Administration (M.Sc Econ.) from Åbo Akademi Business School and Political Science (M.Sc) from University of Turku.

dr. Manu Tamminen

Dr. Manu Tamminen

CTO

Dr. Tamminen is the head of R&D at Genomill Health. Dr. Tamminen is an expert in molecular biology, next-generation DNA sequencing and bioinformatics. He received his PhD from the University of Helsinki and did his post-doctoral research at MIT and ETH Zürich, where he developed methodologies for single cell sequencing and molecular counting. He is currently an Adjunct Professor and Lecturer of Genetics at the University of Turku and has authored several high-impact research publications. His experience also includes consulting for emerging biotech companies.

Sami Savisalo

Sami Savisalo

LEGAL ADVISOR

Mr. Savisalo is an experienced legal professional positioned in a Finnish law firm publicly listed on Nasdaq First North Finland. Mr. Savisalo has a strong experience in intellectual property rights and complex and business-critical agreements within the life science industry. He also counsels regularly investors and target companies in venture capital investments and sellers and purchasers in mergers and acquisitions. Mr. Savisalo holds Master of Laws (LL.M) degree from University of Turku.

Petri Elo

Petri Elo

Logistics Manager & Business Developer

Mr. Elo  is the Logistics Manager & Business Developer at Genomill Health. He joined the company as an early employee in the beginning of 2017. His responsibilities include the logistics of the genetic tests services, and acquiring new and managing existing customers. Mr. Elo holds a M.Sc. (Health Biosciences) from the University of Turku. He has also experience in establishing and managing scientific research projects during his PhD at the University of Turku.

OUR ADVISORS

Dr. Jukka Laine

Dr. Jukka Laine

Medical Advisor

Dr. Jukka Laine (M.D, Ph.D.) is acting as medical advisor at GenoMill Health. Mr. Laine is an experienced pediatric pathologist, with 20 years of clinical career as a specialist. He has been actively working in Pediatric Pathology Society and he is a Graduate from registered IPPA (International Pediatric Pathology Association) course. His special research interest are fetal and pediatric diseases and cancer, with the present focus on the genetics of fetal and neonatal death and chromosomal abnormalities and he has 84 peer reviewed scientific publications. Mr. Laine is currently an Associate Professor at University of Turku.

Panu Jaakkola

Dr. Panu Jaakkola

MD, PhD

Adj. Professor, Specialist in Oncology and Radiotherapy  Head of Turku University Hospital Cancer Center

Jussi Koivunen

Dr. Jussi Koivunen, MD, PhD

Adj. Prof. Exp Oncology

Specialist in Medical and Radiation Oncology